March 26, 2021
AstraZeneca pushes back vaccines-in-Italy topic
AstraZeneca has issued a statement to clarify a number of inaccurate statements relating to COVID-19 Vaccine AstraZeneca doses at the Anagni plant in Italy.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
March 26, 2021
Novadiscovery, Takeda in new clinical simulation collaboration
Novadiscovery has entered into a new collaboration with Takeda Pharmaceutical Company Limited (“Takeda”) aimed at incorporating clinical simulation technology on virtual patients into Takeda France’s access strategy.
March 25, 2021
AstraZeneca answers accusation to stockpiling vaccines; 13M doses for COVAX, 16M for Europe
AstraZeneca has denied accusations of stockpiling vaccines stating that the process of manufacturing vaccines is very complex and time consuming…
March 24, 2021
Novo Nordisk weight loss drug shows good results in a 68-week trial
Novo Nordisk’a new results from the STEP phase 3a clinical trial programme showed weight loss with investigational treatment of once-weekly subcutaneous semaglutide 2.4 mg versus placebo.
March 24, 2021
Bayer’s NTRK fusion-positive tumor drug approved in Japan
Bayer has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for larotrectinib, under the brand name Vitrakvi, for the treatment of Neurotrophic Tyrosine Receptor Kinase (NTRK) fusion-positive advanced or recurrent solid tumors.
March 23, 2021
Investigational AstraZeneca vaccine prevents COVID-19
Results from a large clinical trial in the United States and South America indicate that AstraZeneca’s COVID-19 vaccine, AZD1222, is…
March 19, 2021
UK and EU regulatory agencies confirm COVID-19 Vaccine AstraZeneca is safe and effective
Today the Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines Agency (EMA) reaffirmed the benefits of COVID-19 Vaccine AstraZeneca continue to far outweigh the risks.
March 15, 2021
Sanofi, Regeneron post positive results in P3 testing of Libtayo (oncology) monotherapy
Sanofi and Regeneron posted positive results with an overall survival (OS) benefit from the Phase 3 trial investigating its PD-1 inhibitor Libtayo (cemiplimab) monotherapy compared to chemotherapy in patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.
March 15, 2021
Roche buys genMak for $1.8 billion
Roche is buying GenMark at a price of US$ 24.05 per share in an all-cash transaction, the companies announced Monday agreement with a total transaction value of approximately US$ 1.8 billion.
March 14, 2021
AstraZeneca responds to another country halting use of its vaccine
Ireland has temporarily halted using AstraZeneca’s Covid-19 vaccine Sunday, which came after a report from Norway of patients developing blood clots post inoculation.